Purpose: To analyze the impact of neoadjuvant hormone therapy (HT) on acute gastrointestinal (GI) and genitourinary (GU) toxicity from radiotherapy (RT). Scope: The toxicity rates of 480 consecutive prostate cancer patients were reviewed and compared using the v 2 test. Ordered logit regression analyses were performed including the major demographic, disease, and treatment factors. Although no reduction in acute GI toxicity from HT use was observed (P ¼ 0.067), a lower rate of acute GU toxicity was observed (P ¼ 0.002). No factor reached statistical significance on regression analysis. Conclusions: Observed toxicity rates were similar or lower in patients receiving HT. Thus, increased RT toxicity should not be a concern when deciding to add neoadjuvant HT to RT for prostate cancer.
Introduction
Prostate cancer is one of the most common malignancies diagnosed and treated. 1, 2 Significant progress has been made in the screening, diagnosis, and management of prostate cancer. Radiotherapy (RT) occupies a central role in the management of solid tumors, and is commonly used with curative intent for locally advanced, localized, and postprostatectomy prostate cancer. External beam radiotherapy (EBRT) has developed from earlier techniques to the recently developed intensitymodulated radiotherapy (IMRT). 3 The other major technique of delivering radiation is interstitial brachytherapy, performed by placement of either permanent or temporary radioactive sources. 1 Numerous studies have documented the role of technology advancements in EBRT and brachytherapy in improving outcomes. These improvements in the delivery of radiotherapy have continually improved the ability to deliver therapeutic doses of radiotherapy, and with available followup have improved cancer control outcomes. [4] [5] Hormone therapy (HT) is used ubiquitously for locally advanced, localized, and postprostatectomy prostate cancer, and occupies a central role in the management of metastatic and recurrent disease. Because of the dependence of prostate cancer on testosterone, HT (also termed androgen ablation) 6 is used throughout a wide range of disease presentation. After success in the setting of metastatic prostate cancer, [7] [8] subsequent efforts involved the use of hormones with local treatment, predominantly RT, for locally advanced disease. Combination HT and RT is commonly used in many prostate cancer settings and has been successful for two primary reasons: (a) HT and RT have different mechanisms of action on tumor cell kill, enhancing cure rate and (b) the side effects of the two treatments are different. 9 The role of HT in combination with RT for locally advanced prostate cancer has been examined by numerous investigators, with an advantage having been demonstrated in a number of randomized trials. [10] [11] [12] [13] [14] [15] [16] This success of HT in the metastatic and locally advanced settings set the stage for the use of hormones in earlystage disease, in which there is a preponderance of retrospective data [17] [18] [19] [20] [21] [22] [23] [24] and recently one randomized trial in the intermediate/high-risk group within this localized population. 25 Several prior investigations have examined the toxicity of HT. The sequelae of hormones are well-documented and include hot flashes, weight gain, fatigue, and loss of libido. 9, 26 Systematic efforts have been undertaken to analyze these effects in relation to the efficacy of RT in various settings 16, 24, 27 and have generally found that despite these side effects, adjuvant HT is of benefit when used with RT in virtually all settings of non-metastatic prostate cancer, with the exception of the earliest stage/ favorable risk subgroups, for which more data are needed.
These hormone-specific side effects are not, however, the focus of the current investigation, which seeks to quantify the impact of HT on RT toxicity. The influence of HT on acute and late RT toxicity has been the subject of several prior investigations. [28] [29] [30] [31] [32] [33] [34] [35] One major theoretical advantage of neoadjuvant HT is the potential for cytoreduction of the prostate to reduce the overlap of the treatment volume with the surrounding bladder and rectum-indeed, several investigators have documented the potential role of cytoreduction in improving rectal and bladder dose volume histograms for EBRT 29, 30, 32, 34 and in reducing the number of needles/ seeds for interstitial brachytherapy. 33 This potential for reducing toxicity is countered, however, by (a) the potential for reducing normal tissue tolerance and (b) if RT planning is done while the HT is still causing continued cytoreduction, the possibility of the RT treatment fields being overly generous for the still-shrinking prostate. Indeed, some investigators have reported an increase in acute GU toxicity (a finding limited to those with poor baseline urinary function), 28 and an increase in late GI toxicity 31 with the addition of HT to RT. Using the smaller post-HT fields does carry the risk, however, of not reaching disease at the periphery of the pre-HT prostate. 35 The majority of the investigations listed above were dosimetric studies, without correlative clinical outcomes, or were multi-institutional that were subject to variations in treatment techniques across different hospitals. The message from the currently developed literature is, as described above, somewhat mixed, with studies demonstrating both the positive and negative impact of HT on RT toxicity. It remains crucial, however, to understand the impact of HT on RT toxicity, both because treatment decisions in prostate cancer are often based on toxicity, and because HT has been proposed in selected patients to serve as a surrogate for RT dose escalation.
The goal of this report is to understand the features of the hormone/RT interaction in the setting of RT administered as primary treatment for the intact prostate, with particular regard to acute gastrointestinal (GI) and genitourinary (GU) sequelae. The major goal of the study is to analyze clinical outcomes, not dosimetric outcomes. One of the major strength of our study is that it is a single-institution analysis, so we can assess the toxicity rates in a setting where inter-institutional differences in treatment technique can be avoided.
Materials and methods
The charts of consecutive prostate cancer patients treated at our institution from 1993 through 2003 were reviewed. In all, 610 consecutive patients who were diagnosed with nonmetastatic prostate cancer, treated with RT (EBRT, brachytherapy, or both), and for whom demographic, treatment, and follow-up information were available were identified. Patients receiving post-prostatectomy RT or brachytherapy were excluded from the analysis, resulting in 480 patients forming the database for the current analysis.
In general, initial workup included a serum PSA and digital rectal examination and, where appropriate, a bone scan and/or CT scan (for PSA415 ng/ml); these radiological tests, if ordered, were required to be negative for metastases. The patients were treated at a single institution, and uniform guidelines were used in RT simulation and treatment planning. Regarding EBRT, 18 MV photons (during the 4-field and 6-field conformal eras, prior to 2000) or 6 MV photons (during the IMRT era, since late 2000) were used, with 1.8 or 2.0 Gy fractions delivered once-daily to achieve a final dose (prescribed as minimum dose to a treatment target, typically 1 cm uniformly around the prostate and seminal vesicles (localized disease) or whole pelvis (locally advanced disease) for an initial phase to 50.0-50.4 Gy, and a later phase of treatment to the prostate alone expanded by 1 cm) of 66.0-76.4 Gy.
HT, typically administered for patients with adverse prognostic factors, consisted of a combination of testosterone receptor antagonist (flutamide or bicalutamide) and a GnRH agonist (leuprolide or goserelin)-the duration of HT was 4 months to 2 y depending on the severity of the prognostic factors. Specifically, total duration of hormones was 4 months (2 before and 2 months during) RT for localized early-stage prostate cancer (except for the low-risk group, for which HT is not given). For locally advanced disease, again combination testosterone antagonist and GnRH agonist were given, with EBRT delivered after 2 months of hormones. HT was continued during RT, with only the testosterone antagonist discontinued after 4 total months. The GnRH agonist continued, and the total duration of hormones for locally advanced disease is typically 1-2 y (as tolerated). Additional systemic therapy (ie, chemotherapy) was not given to any patient in addition to standard hormones þ EBRT for locally advanced disease. Median follow-up for the cohort was 31.0 months. Table 1 summarizes the patient demographic, disease, and treatment characteristics. As shown in this table, the entire cohort was divided into two general categories based on whether HT was administered. Then, using standard RTOG toxicity grading scales, acute GI and GU toxicity scores 36 were assigned to each patient and were compared using the w 2 test. 37 The study interval for analysis of acute toxicity was from the start of RT to 6 weeks after the completion of RT. Additionally, as a more stringent measure of evaluating the influence of age on toxicity, for each general category of analysis, an ordered logit regression 38 was performed using all major demographic factors (age and race), disease factors (T-stage, N-stage, PSA, and Gleason score) and treatment factors (RT dose and HT). Table 2 displays the analyses for HT þ RT vs RT alone for (a) acute GI toxicity and (b) acute GU toxicity. As Impact of hormone therapy AB Jani et al displayed, there were no significant differences in rates of GI toxicity (Table 2a) . However, the acute GU toxicity (Table 2b ) was significantly lower in the group receiving HT. This advantage appears to be most pronounced in the reduction of grade 1 GU toxicity-there were no appreciable differences in the rates of grade 2 or higher GU toxicity. It should be noted that the lower rates of acute GU toxicity were observed despite there being a slightly higher radiation dose in the group receiving hormones (72.0 vs 70.0 Gy, as displayed in Table 1) . Table 3 displays the results of the ordered logit regression analyses for (a) acute GI and (b) acute GU toxicity. As displayed, no demographic, disease, or treatment factor, including the use of HT, reached statistical significance in predicting either acute GI or acute GU toxicity.
Results

Discussion
HT is increasingly used in combination with RT as prostate cancer control outcomes continue to be reported demonstrating a survival advantage to the use of HT in many settings. Although many studies have analyzed the influence of HT on RT toxicity, the current effort represents one of the largest efforts of its kind (and certainly the largest single-institution report to date) to attempt to understand the influence of HT on acute RT toxicity in a setting where inter-institutional variations in technique can be minimized.
The results observed suggest that acute GU toxicity was lower in those patients receiving HT, but that acute GI toxicity was not significantly different. The biological message of this finding is that hormonal cytoreduction may allow reduction in bladder dose when delivering RT. The finding that most of the toxicity reduction appeared to be in the grade I category suggests that the effect may be more related to reduction in integral dose to the bladder than to a decrease in the volume of the bladder receiving high-dose. Several prior investigations 29, 30, 32, 34 have documented the role of HT in ). Thus, it is our opinion that the potential for increasing RT toxicity should not be a concern for the clinician when making the decision regarding the addition of neoadjuvant HT to RT.
The limitations of the current study are well understood by the authors: First, the biases inherent to a retrospective review are well-recognized. Second, the results described herein are specific to acute toxicity. That is, because RT has both acute and late side effects, the results of the current investigation cannot be extended to late toxicity-this will require its own separate analysis. In a similar vein, the results described herein cannot be extended to postprostatectomy RT patients; in these cases the absence of the prostate makes the cytoreductive effects of HT not relevant, and there may be a fundamentally different interaction of HT with RT in this setting, which must be evaluated independently. Third, the differing lengths of HT between subgroups were considered together (that is, hormone duration was not entered as an independent variable in the analysis); however, this is not a major limitation to interpretation of the results as the neoadjuvant portion of the HT was uniformly administered, and this is the component of the HT that forms the basis of the interaction with RT in influencing acute toxicity results. Also, as displayed in Table 1 , the patients receiving long-term hormones were very small in number. Fourth, as described in the methods section, the treatments changed over the duration of the study from more primitive to more advanced RT techniques; again, however, this does not prohibit interpretation of the results as the treatment techniques evolved in both HT and no-HT groups simultaneously; indeed, as shown in Table 1 , there was a similar rate of use of IMRT in both groups.
Within these above stated limitations, the current study does provide valuable single-institution data on the impact of HT on RT toxicity in nonmetastatic prostate cancer. It is hoped that other institutions continue to report their data for comparison with our experience.
